Lecanemab lowered phosphorylated tau by 23% in clinical trials over nearly 7 years.
"And the drugs that are used for it, lecanemab, they lowered phosphorylated tau by 23% in almost 7 years." (said at 0:30:35)
The claim that lecanemab lowered phosphorylated tau by 23% over nearly 7 years is contradicted by clinical trial evidence. In the primary Phase 3 clinical trial (Clarity AD), lecanemab was evaluated over an 18-month (1.5-year) double-blind period, not 7 years. While lecanemab significantly reduced amyloid markers and slowed clinical decline compared with placebo at 18 months, published clinical trials and long-term pharmacodynamic modeling evaluate outcomes over 18 months to 4 years, making the claimed 7-year timeframe inaccurate.
- contradicts: Lecanemab in Early Alzheimer's Disease. (The New England journal of medicine 2023)
"We conducted an 18-month, multicenter, double-blind, phase 3 trial involving persons 50 to 90 years of age with early Alzheimer's disease (mild cognitive impairment or mild dementia due to Alzheimer's disease) with evidence of amyloid on positron-emission tomography (PET) or by cerebrospinal fluid testing." (abstract, methods, passage verified)
pubmedfull study (doi) - contradicts: Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects … (Alzheimer's & dementia (New York, N. Y.) 2026)
"Simulations were conducted to evaluate the effect of lecanemab (10 mg/kg IV every 2 weeks, LEC10-BW) after 4 years of continuous treatment, discontinuation after 18 months of treatment or transitioning to less frequent dosing at 18, 24, or 30 months." (abstract, methods, passage verified)
pubmedfull study (doi)